GLA and Fabry disease: However, a significant difference was not observed in a small clinical study (34 Fabry disease patients) with the same dose treatments (Vedder et al. 2007), later attributed to the marginal difference of M6P contents (agalsidase alfa 2.1 mol/mol and agalsidase beta 2.9 mol/mol) (Togawa et al. 2014).